SCGN and STAT3 expressions are associated with the prognosis of ccRCC.


Journal

Pathology, research and practice
ISSN: 1618-0631
Titre abrégé: Pathol Res Pract
Pays: Germany
ID NLM: 7806109

Informations de publication

Date de publication:
Dec 2023
Historique:
received: 12 09 2023
revised: 16 10 2023
accepted: 09 11 2023
medline: 29 11 2023
pubmed: 18 11 2023
entrez: 17 11 2023
Statut: ppublish

Résumé

Clear cell renal cell carcinoma (ccRCC) is highly heterogeneous and accounts for about 70% of RCC. Its prognosis is worse than that of most histological types of RCC. In order to find potential biomarkers that may influence the prognosis and survival in ccRCC patients, we explored the expressions of STAT3, PDL1 and SCGN (secretagogin) in ccRCC based on the data of TCGA (n = 529), EMATAB-1980 (n = 99) and our own cohort (n = 99). Our study demonstrated that ccRCC patients with low STAT3 expression and high SCGN expression might have a better prognosis. No significant difference in the positive rate of SCGN expression was found when comparing the primary lesion with the matched metastatic liver lesions. The percentage of high SCGN expression in the primary lesion of metastatic ccRCC patients was significantly lower than that of patients with only the renal lesion. In view of the conclusion that STAT3 high expression cases are resistant to sunitinib, STAT3 immunohistochemistry results are essential for designing non-operative treatments. SCGN has the potential to become an indicator for subtype classification of ccRCC.

Identifiants

pubmed: 37977033
pii: S0344-0338(23)00641-6
doi: 10.1016/j.prp.2023.154940
pii:
doi:

Substances chimiques

Biomarkers, Tumor 0
STAT3 protein, human 0
STAT3 Transcription Factor 0
SCGN protein, human 0
Secretagogins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

154940

Informations de copyright

Copyright © 2023 Elsevier GmbH. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest No.

Auteurs

Chong Lai (C)

Department of Urology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.

Jingwen Gong (J)

Department of Pathology, Zhejiang University School of Medicine, Hangzhou, China.

Jinlong Tang (J)

Department of Pathology, the Second affiliated hospital, Zhejiang University School of Medicine, Hangzhou, China.

Qin Liu (Q)

Department of Pathology, Zhejiang University School of Medicine, Hangzhou, China.

Min Zhang (M)

Department of Pathology, Zhejiang University School of Medicine, Hangzhou, China.

Maode Lai (M)

Department of Pathology, Zhejiang University School of Medicine, Hangzhou, China.

Dandan Zhang (D)

Department of Pathology, Zhejiang University School of Medicine, Hangzhou, China. Electronic address: dandanz@zju.edu.cn.

Xiaodong Teng (X)

Department of Pathology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. Electronic address: teng1102069@zju.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH